Quantification of Myocardial Blood Flow: What is the Clinical Role?

Cardiology Clinics

Volumn 27, Issue 2, 2009, Pages 277-289

  Schelbert, Heinrich R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary artery disease; Endothelial function; Microvascular disease; Myocardial blood flow; PET

Indexed keywords

AMMONIA N 13; CARBON 11; RUBIDIUM 82; TECHNETIUM 99M; VASODILATOR AGENT; WATER O 15;

BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC PROCEDURE; ENDOTHELIUM; EPICARDIUM; FLOW MEASUREMENT; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; ISCHEMIA; KINETICS; MICROANGIOPATHY; MICROVASCULATURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR DISEASE; VASODILATATION; VASOMOTOR REFLEX;

CORONARY CIRCULATION; CORONARY DISEASE; CORONARY VESSELS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS;

EID: 62549121191     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.12.009     Document Type: Review

References (80)

1. Bergmann S.R., Herrero P., Markham J., et al. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 14 (1989) 639-652
2. El Fakhri G., Sitek A., Guerin B., et al. Quantitative dynamic cardiac 82Rb PET using generalized factor and compartment analyses. J Nucl Med 46 (2005) 1264-1271
3. Hutchins G.D., Schwaiger M., Rosenspire K.C., et al. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 15 (1990) 1032-1042
4. Iida H., Kanno I., Takahashi A., et al. Measurement of absolute myocardial blood flow with H215O and dynamic positron-emission tomography. Strategy for quantification in relation to the partial-volume effect. Circulation 78 (1988) 104-115
5. Krivokapich J., Smith G.T., Huang S.C., et al. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation 80 (1989) 1328-1337
6. Lortie M., Beanlands R.S., Yoshinaga K., et al. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 34 (2007) 1765-1774
7. Hermansen F., Ashburner J., Spinks T.J., et al. Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. J Nucl Med 39 (1998) 1696-1702
8. Schelbert H.R., Phelps M.E., Huang S.C., et al. N-13 ammonia as an indicator of myocardial blood flow. Circulation 63 (1981) 1259-1272
9. Choi Y., Huang S.C., Hawkins R.A., et al. Quantification of myocardial blood flow using 13N-ammonia and PET: comparison of tracer models. J Nucl Med 40 (1999) 1045-1055
10. Bergmann S.R., Fox K.A., Rand A.L., et al. Quantification of regional myocardial blood flow in vivo with H215O. Circulation 70 (1984) 724-733
11. Bol A., Melin J.A., Vanoverschelde J.L., et al. Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres. Circulation 87 (1993) 512-525
12. Kuhle W.G., Porenta G., Huang S.C., et al. Quantification of regional myocardial blood flow using 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 86 (1992) 1004-1017
13. Muzik O., Beanlands R.S., Hutchins G.D., et al. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 34 (1993) 83-91
14. Lautamaki R., George R.T., Kitagawa K., et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol Imaging (2008)
15. Jagathesan R., Kaufmann P.A., Rosen S.D., et al. Assessment of the long-term reproducibility of baseline and dobutamine-induced myocardial blood flow in patients with stable coronary artery disease. J Nucl Med 46 (2005) 212-219
16. Kaufmann P.A., Gnecchi-Ruscone T., Yap J.T., et al. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med 40 (1999) 1848-1856
17. Nagamachi S., Czernin J., Kim A.S., et al. Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET. J Nucl Med 37 (1996) 1626-1631
18. Sawada S., Muzik O., Beanlands R.S., et al. Interobserver and interstudy variability of myocardial blood flow and flow-reserve measurements with nitrogen 13 ammonia-labeled positron emission tomography. J Nucl Cardiol 2 (1995) 413-422
19. Schindler T.H., Zhang X.L., Prior J.O., et al. Assessment of intra- and interobserver reproducibility of rest and cold pressor test-stimulated myocardial blood flow with (13)N-ammonia and PET. Eur J Nucl Med Mol Imaging 34 (2007) 1178-1188
20. Siegrist P.T., Gaemperli O., Koepfli P., et al. Repeatability of cold pressor test-induced flow increase assessed with H(2)(15)O and PET. J Nucl Med 47 (2006) 1420-1426
21. Wyss C.A., Koepfli P., Namdar M., et al. Tetrahydrobiopterin restores impaired coronary microvascular dysfunction in hypercholesterolaemia. Eur J Nucl Med Mol Imaging 32 (2005) 84-91
22. Camici P.G., and Crea F. Coronary microvascular dysfunction. N Engl J Med 356 (2007) 830-840
23. Heusch G., Baumgart D., Camici P., et al. alpha-adrenergic coronary vasoconstriction and myocardial ischemia in humans. Circulation 101 (2000) 689-694
24. Zeiher A.M., Drexler H., Wollschlaeger H., et al. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol 14 (1989) 1181-1190
25. Zeiher A.M., Drexler H., Wollschlager H., et al. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83 (1991) 391-401
26. Zeiher A.M., Drexler H., Wollschlager H., et al. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 84 (1991) 1984-1992
27. Chan S.Y., Brunken R.C., Czernin J., et al. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 20 (1992) 979-985
28. Heinonen I., Nesterov S.V., Liukko K., et al. Myocardial blood flow and adenosine A2A receptor density in endurance athletes and untrained men. J Physiol 586 (2008) 5193-5202
29. Kubo S., Tadamura E., Toyoda H., et al. Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. J Nucl Med 45 (2004) 730-738
30. Buus N.H., Bottcher M., Hermansen F., et al. Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation 104 (2001) 2305-2310
31. Campisi R., Czernin J., Schoder H., et al. Effects of long-term smoking on myocardial blood flow, coronary vasomotion, and vasodilator capacity. Circulation 98 (1998) 119-125
32. Schindler T.H., Nitzsche E.U., Olschewski M., et al. PET-measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. J Nucl Med 45 (2004) 419-428
33. Prior J.O., Schindler T.H., Facta A.D., et al. Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans. Eur J Nucl Med Mol Imaging 34 (2007) 20-27
34. Gould K.L., Nakagawa Y., Nakagawa K., et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base-to-apex myocardial perfusion abnormalities by noninvasive positron emission tomography. Circulation 101 (2000) 1931-1939
35. De Bruyne B., Hersbach F., Pijls N.H., et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography. Circulation 104 (2001) 2401-2406
36. Hernandez-Pampaloni M., Keng F.Y., Kudo T., et al. Abnormal longitudinal, base-to-apex myocardial perfusion gradient by quantitative blood flow measurements in patients with coronary risk factors. Circulation 104 (2001) 527-532
37. Schindler T.H., Facta A.D., Prior J.O., et al. PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction. Eur J Nucl Med Mol Imaging 33 (2006) 1140-1149
38. Neglia D., and L'Abbate A. Myocardial perfusion reserve in ischemic heart disease. J Nucl Med 50 (2009) 175-177
39. Parkash R., deKemp R.A., Ruddy T.D., et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 11 (2004) 440-449
40. Di Carli M., Czernin J., Hoh C.K., et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 91 (1995) 1944-1951
41. Uren N.G., Melin J.A., De Bruyne B., et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 330 (1994) 1782-1788
42. Cecchi F., Olivotto I., Gistri R., et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
43. Neglia D., Michelassi C., Trivieri M.G., et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105 (2002) 186-193
44. Stolen K.Q., Kemppainen J., Kalliokoski K.K., et al. Myocardial perfusion reserve and peripheral endothelial function in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 93 (2004) 64-68
45. Olivotto I., Cecchi F., Gistri R., et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 47 (2006) 1043-1048
46. Tio R.A., Dabeshlim A., Siebelink H.-M.J., et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med 50 2 (2009) 214-219
47. Maron B.J., Wolfson J.K., Epstein S.E., et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8 (1986) 545-557
48. Yokoyama I., Yonekura K., Ohtake T., et al. Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease. J Nucl Med 41 (2000) 978-985
49. Schindler T.H., Facta A.D., Prior J.O., et al. Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. Heart 93 (2007) 345-349
50. Yokoyama I., Ohtake T., Momomura S., et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes 47 (1998) 119-124
51. Gistri R., Cecchi F., Choudhury L., et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 74 (1994) 363-368
52. Mourad J.J., Hanon O., Deverre J.R., et al. Improvement of impaired coronary vasodilator reserve in hypertensive patients by low-dose ACE inhibitor/diuretic therapy: a pilot PET study. J Renin Angiotensin Aldosterone Syst 4 (2003) 94-95
53. Dayanikli F., Grambow D., Muzik O., et al. Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 90 (1994) 808-817
54. Pitkanen O.P., Nuutila P., Raitakari O.T., et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 99 (1999) 1678-1684
55. Sundell J., Laine H., Raitakari O.T., et al. Positive family history of coronary artery disease is associated with reduced myocardial vasoreactivity in healthy men. Int J Cardiol 112 (2006) 289-294
56. Yokoyama I., Murakami T., Ohtake T., et al. Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med 37 (1996) 1937-1942
57. Yokoyama I., Ohtake T., Momomura S., et al. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation 94 (1996) 3232-3238
58. Yokoyama I., Ohtake T., Momomura S., et al. Altered myocardial vasodilatation in patients with hypertriglyceridemia in anatomically normal coronary arteries. Arterioscler Thromb Vasc Biol 18 (1998) 294-299
59. Yokoyama I., Ohtake T., Momomura S., et al. Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia. J Am Coll Cardiol 31 (1998) 1568-1574
60. Campisi R., Nathan L., Pampaloni M.H., et al. Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. Circulation 105 (2002) 425-430
61. Schindler T.H., Cardenas J., Prior J.O., et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 47 (2006) 1188-1195
62. Schindler T.H., Nitzsche E.U., Schelbert H.R., et al. Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol 45 (2005) 1505-1512
63. Prior J.O., Quinones M.J., Hernandez-Pampaloni M., et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111 (2005) 2291-2298
64. Rask-Madsen C., and King G.L. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3 (2007) 46-56
65. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
66. Schindler T.H., Nitzsche E.U., Munzel T., et al. Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: contrasting myocardial blood flow responses to short- and long-term vitamin C administration. J Am Coll Cardiol 42 (2003) 814-822
67. Czernin J., Barnard R.J., Sun K.T., et al. Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation 92 (1995) 197-204
68. Baller D., Notohamiprodjo G., Gleichmann U., et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
69. Guethlin M., Kasel A.M., Coppenrath K., et al. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 99 (1999) 475-481
70. Huggins G.S., Pasternak R.C., Alpert N.M., et al. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 98 (1998) 1291-1296
71. Yokoyama I., Momomura S., Ohtake T., et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation 100 (1999) 117-122
72. Quinones M.J., Hernandez-Pampaloni M., Schelbert H., et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140 (2004) 700-708
73. Fichtlscherer S., Breuer S., and Zeiher A.M. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. Circulation 110 (2004) 1926-1932
74. Modena M.G., Bonetti L., Coppi F., et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 40 (2002) 505-510
75. Madar I., Ravert H., Dipaula A., et al. Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med 48 (2007) 1021-1030
76. Madar I., Ravert H.T., Du Y., et al. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med 47 (2006) 1359-1366
77. Yu M., Guaraldi M., Kagan M., et al. Assessment of (18)F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates. Eur J Nucl Med Mol Imaging 36 (2009) 63-72
78. Yu M., Guaraldi M.T., Mistry M., et al. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol 14 (2007) 789-798
79. Higuchi T., Nekolla S.G., Huisman M.M., et al. A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats. J Nucl Med 49 (2008) 1715-1722
80. Maddahi J., Schiepers C., Czernin J., et al. First human study of BMS747158, a novel F-18 labeled tracer for myocardial perfusion imaging. J Nucl Med 49 (2008) 70P